{"protocolSection": {"identificationModule": {"nctId": "NCT01231230", "orgStudyIdInfo": {"id": "20060346"}, "organization": {"fullName": "University of Miami", "class": "OTHER"}, "briefTitle": "Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway", "officialTitle": "Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway"}, "statusModule": {"statusVerifiedDate": "2016-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-05"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-25", "studyFirstSubmitQcDate": "2010-10-29", "studyFirstPostDateStruct": {"date": "2010-11-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-03-24", "resultsFirstSubmitQcDate": "2014-12-03", "resultsFirstPostDateStruct": {"date": "2014-12-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-05-27", "lastUpdatePostDateStruct": {"date": "2016-06-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Adam Wanner", "investigatorTitle": "Professor of Medicine", "investigatorAffiliation": "University of Miami"}, "leadSponsor": {"name": "University of Miami", "class": "OTHER"}, "collaborators": [{"name": "GlaxoSmithKline", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The addition of an inhaled long-acting beta-adrenergic agonist to an inhaled glucocorticosteroid improves disease control in persistent asthma. This observation has supported the use of long-acting beta-adrenergic agonist/glucocorticosteroid combination preparations for the management of asthma. Currently, salmeterol/fluticasone and formoterol/budesonide are available for clinical use. The long-term beneficial clinical effects of the two drug classes seem to be synergistic, and several mechanisms of glucocorticoid-beta-adrenergic agonist interactions involving gene transcription have been invoked to explain this phenomenon.This study, wish to address the question whether glucocorticoids can acutely potentiate the bronchodilator response to a long-acting beta-adrenergic agonist.We expect that in patients with asthma, the short-term bronchodilator effect of salmeterol is enhanced by the addition of fluticasone, which by itself has no short-term bronchodilator effect. To test this premise, we will assess the respective short-term effects of salmeterol (50 \u00b5g), fluticasone (250 \u00b5g), salmeterol/fluticasone (50/250 \u00b5g), and placebo/placebo on spirometric parameters. Airway Blood flow will also be measured to ensure that vasoconstriction does not occur.", "detailedDescription": "Fourteen lifetime nonsmokers with a physician diagnosis of asthma will be recruited for the study. All subjects will be allowed to use short-acting beta-adrenergic agonists as rescue medication.\n\nInclusion criteria:\n\n1. Males and females, 18 to 65 years of age.\n2. FEV1 60-85% of predicted on the screening day.\n\nExclusion criteria:\n\n1. Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women.\n2. Cardiovascular disease and/or use of cardiovascular medications\n\n2. Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance 4. Acute respiratory infection within four weeks prior to the study 5. Use, within two weeks prior to the study, of any anti-asthma medication not mentioned above"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthma, corticosteroids, bronchodilator, airway blood flow"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 14, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "fluticasone/salmeterol", "type": "EXPERIMENTAL", "description": "participants were treated fluticasone/salmeterol,", "interventionNames": ["Drug: fluticasone/salmeterol"]}, {"label": "salmeterol", "type": "EXPERIMENTAL", "description": "participants were treated with salmeterol", "interventionNames": ["Drug: Salmeterol"]}, {"label": "fluticasone", "type": "EXPERIMENTAL", "description": "participants were treated with fluticasone", "interventionNames": ["Drug: fluticasone"]}, {"label": "placebo inhalation", "type": "PLACEBO_COMPARATOR", "description": "participants were treated with placebo", "interventionNames": ["Drug: placebo inhalation"]}], "interventions": [{"type": "DRUG", "name": "fluticasone", "description": "220- mcg once", "armGroupLabels": ["fluticasone"], "otherNames": ["flovent"]}, {"type": "DRUG", "name": "placebo inhalation", "description": "placebo inhalation once", "armGroupLabels": ["placebo inhalation"], "otherNames": ["sugar pill"]}, {"type": "DRUG", "name": "Salmeterol", "description": "50 mcg salmeterol once", "armGroupLabels": ["salmeterol"], "otherNames": ["serevent"]}, {"type": "DRUG", "name": "fluticasone/salmeterol", "description": "inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol", "armGroupLabels": ["fluticasone/salmeterol"], "otherNames": ["advair"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Change From Baseline in Airway Blood Flow (Qaw)", "timeFrame": "maximum change in Qaw within 240 minutes post drug inhalation"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Males and females, 18 to 65 years of age.\n2. FEV1 60-85% of predicted on the screening day. -\n\nExclusion Criteria:\n\n1. Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women. 2. Cardiovascular disease and/or use of cardiovascular medications 3. Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance 4. Acute respiratory infection within four weeks prior to the study 5. Use, within two weeks prior to the study, of any anti-asthma medication not mentioned above\n\n-", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Adam Wanner, MD", "affiliation": "University of Miami", "role": "PRINCIPAL_INVESTIGATOR"}]}, "referencesModule": {"references": [{"pmid": "21980058", "type": "DERIVED", "citation": "Mendes ES, Rebolledo P, Wanner A. Acute effects of salmeterol and fluticasone propionate alone and in combination on airway blood flow in patients with asthma. Chest. 2012 May;141(5):1184-1189. doi: 10.1378/chest.11-0685. Epub 2011 Oct 6."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Subjects were recruited from our Asthma Database. Subjects with asthma who are in our database have previously agreed to serve as potential subjects in future studies. These subjects have signed an informed consent (approved by UM IRB) to be included in this database.", "groups": [{"id": "FG000", "title": "All Study Groups", "description": "inhalation of 250 mcg of fluticasone\n\nfluticasone: 220- mcg once"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "Fluticasone", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "Salmeterol", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "Fluticasone/Salmeterol", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "Placebo", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Fourteen lifetime nonsmokers with a physician diagnosis of asthma were recruited for the study. All but one of the subjects were using an ICS/LABA combination preparation regularly, and all used a short-acting b2-adrenergic agonist as rescue medication. All subjects had to have a prebronchodilator FEV1 of 60% to 85% predicted .", "groups": [{"id": "BG000", "title": "All Study Participants", "description": "participant received in random order one of the four treatments ( fluticasone, salmeterol, fluticasone+salmeterol or placebo)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "14"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "14"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}]}, {"title": "Airway blood flow (Qaw)", "description": "Qaw was measured with a previously validated soluble inert gas uptake method. It is based on quantifying the disappearance of the soluble gas dimethylether (DME) from the anatomical dead space. The method involves the inhalation of a gas mixture containing 10 % DME and 90% nitrogen from 500 ml below the total lung capacity position to total lung capacity, followed by a breathhold (5 or 15 sec) and subsequent exhalation while the instantaneous concentrations of DME and nitrogen are recorded.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "\u00b5l.min-1.ml-1", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.8", "spread": "2.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Change From Baseline in Airway Blood Flow (Qaw)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "change from baseline ( \u00b5l/min/ml)", "timeFrame": "maximum change in Qaw within 240 minutes post drug inhalation", "groups": [{"id": "OG000", "title": "Fluticasone", "description": "inhalation of 250 mcg of fluticasone\n\nfluticasone: 220- mcg once"}, {"id": "OG001", "title": "Placebo", "description": "inhalation of placebo diskus\n\nplacebo inhalation: placebo inhalation once"}, {"id": "OG002", "title": "Salmeterol", "description": "inhalation of salmeterol 50 mcg once\n\nSalmeterol: 50 mcg salmeterol once\n\nSalmeterol: 50 mcg once"}, {"id": "OG003", "title": "Fluticasone/Salmeterol", "description": "inhalation of fluticasone 250mcg combined with salmeterol 50 mcg\n\nfluticasone/salmeterol: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "14"}, {"groupId": "OG003", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.0", "spread": "2.9"}, {"groupId": "OG001", "value": "14.1", "spread": "1.9"}, {"groupId": "OG002", "value": "23.9", "spread": "3.6"}, {"groupId": "OG003", "value": "25.5", "spread": "4.7"}]}]}], "analyses": [{"groupIds": ["OG001", "OG003"], "groupDescription": "mean difference from baseline relative to placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "< 0.001", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "15", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "mean difference from baseline relative to placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANOVA", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "mean difference from baseline relative to placebo", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": ">0.05", "statisticalMethod": "ANOVA", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Fluticasone", "description": "inhalation of 250 mcg of fluticasone\n\nfluticasone: 220- mcg once", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}, {"id": "EG001", "title": "Placebo", "description": "inhalation of placebo diskus\n\nplacebo inhalation: placebo inhalation once", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}, {"id": "EG002", "title": "Salmeterol", "description": "inhalation of salmeterol 50 mcg once\n\nSalmeterol: 50 mcg salmeterol once\n\nSalmeterol: 50 mcg once", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}, {"id": "EG003", "title": "Fluticasone/Salmeterol", "description": "inhalation of fluticasone 250mcg combined with salmeterol 50 mcg\n\nfluticasone/salmeterol: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 0, "otherNumAtRisk": 14}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Adam Wanner, MD", "organization": "University of Miami", "email": "awanner@med.miami.edu", "phone": "(305)243-2568"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Blood culture", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}